Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2022-11-21 Capital/Financing Update
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
KOLINPHARMA,IL CONSIGLIO DI AMMINISTRAZIONE DELIBERA L'EMISSIONE DI UN PRESTITO OBBLIGAZIONARIO NON CONVERTIBILE DELL'IMPORTO PARI A EURO 4 MILIONI
Capital/Financing Update Classification · 1% confidence The document is an official communication from KOLINPHARMA S.P.A. to Euronext Growth Milan, dated November 21, 2022. The subject ('Oggetto') explicitly states that the Board of Directors resolved on the 'EMISSIONE DI UN PRESTITO OBBLIGAZIONARIO NON CONVERTIBILE DELL'IMPORTO PARI A EURO 4 MILIONI' (Issuance of a non-convertible bond loan for the amount of Euro 4 million). This action directly relates to the company raising capital or changing its financing structure. Based on the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). It is not an earnings release, an annual report, or a general regulatory filing, but a specific announcement about debt issuance.
2022-11-21 Italian
Kolinpharma, aggiornamento buy back
Transaction in Own Shares Classification · 1% confidence The document is titled 'COMUNICATO STAMPA PRICE SENSITIVE' (Price Sensitive Press Release) and the subject ('Oggetto') is 'Kolinpharma, aggiornamento buy back' (Kolinpharma, buy back update). The content explicitly details the status of the company's share repurchase program ('Programma di ri-acquisto azioni proprie') for a specific period (October 31 - November 4, 2022), stating that no purchases were made and reporting the total number of treasury shares held. This directly relates to the company buying back or selling its own shares. Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length is relatively short (4730 chars) and functions as a notification/update, not a comprehensive report.
2022-11-09 Italian
kolinpharma, aggiornamento buy back
Transaction in Own Shares Classification · 1% confidence The document is titled 'Comunicazione sullo stato di attuazione del Programma di ri-acquisto azioni proprie' (Communication on the status of implementation of the share buyback program) and reports on transactions (or lack thereof) related to the company buying back its own shares for the period October 24-28, 2022. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase reports. Although it is a 'Comunicato Stampa Price Sensitive', the core content is the update on the share repurchase program, making POS the most specific classification over a general RPA or RNS.
2022-11-09 Italian
KOLINPHARMA, KPI 3Q 2022, IN CRESCITA A VOLUMI E VALORI
Earnings Release Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from KOLINPHARMA dated November 3, 2022. The subject line explicitly mentions 'KPI 3Q 2022' (Key Performance Indicators for the Third Quarter of 2022). The content details the growth in medical prescriptions (volumes and values) for the third quarter and the first nine months of 2022. This content structure—a brief announcement summarizing key operational and financial metrics for a specific interim period (Q3)—is characteristic of an Earnings Release (ER), which provides the initial highlights before a more comprehensive report might follow. Since it focuses on period-specific performance indicators rather than being a full, comprehensive report (like an IR or 10-K), ER is the most appropriate classification. The document is short and announces results, fitting the pattern for an ER. Q3 2022
2022-11-03 Italian
Kolinpharma, aggiornamento buy-back
Transaction in Own Shares Classification · 1% confidence The document is titled "Comunicazione sullo stato di attuazione del Programma di ri-acquisto azioni proprie" (Communication on the status of implementation of the share buy-back program) and is explicitly labeled as a "COMUNICATO STAMPA PRICE SENSITIVE" (Price Sensitive Press Release). It reports on the company's holdings of treasury shares for the period October 17-21, 2022. A share buy-back program (repurchase of own shares) directly relates to the company's capital structure and share count. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS). Although it is a press release, the core subject matter is the transaction itself, making POS more specific than RPA or RNS. The document length (4998 chars) is borderline, but the content is a direct report on the buy-back activity, not just an announcement that a report is attached.
2022-10-26 Italian
KOLINPHARMA® SIGNS AN IMPORTANT THREE-YEAR AGREEMENT FOR THE DISTRIBUTION OF PRODUCTS IN MAINLAND CHINA, HONG KONG, MACAO E TAIWAN
Regulatory Filings Classification · 1% confidence The document is a formal announcement from KOLINPHARMA S.p.A. dated October 25, 2022, detailing the signing of a significant three-year distribution agreement with AstaReal® AB for products in Mainland China, Hong Kong, Macao, and Taiwan. The structure, metadata (Informazione Regolamentata), and content focus entirely on a major commercial development and partnership, which is a type of corporate news release. This type of announcement, which is not a financial report (10-K, IR, ER), a management change (MANG), or a shareholder vote result (DVA), fits best under the general category of a Regulatory Filing or a specific announcement type. Since it details a major commercial transaction/partnership, it is a significant corporate event announcement. Given the options, it is a general regulatory announcement, but the content strongly suggests a material event disclosure. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP/SHA). It is a press release announcing a strategic business development. In the context of the provided definitions, this is a general regulatory announcement that doesn't fit the highly specific financial or governance codes. Therefore, the most appropriate fallback is Regulatory Filings (RNS), as it is a formal disclosure to the market, or potentially a general announcement if a more specific 'Business Development' code existed. Given the available codes, RNS is the best fit for a material, non-financial-specific regulatory disclosure.
2022-10-25 Portuguese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.